The idea of ​​diversifying the sources of acquisition of a vaccine more and more advocated

The authorities in Morocco who had announced the arrival in December of 65 million doses of the vaccine from the Chinese pharmaceutical giant Sinopharm and the British AstraZeneca / Oxford to inoculate “25 million” Moroccans according to the Minister of Health Khalid Ait Taleb, had to swallow their ardor since the Kingdom is still waiting for any deliveries which were normally scheduled, according to their good words, for December.

Also and in the absence of being able to benefit from it immediately, a certain number of Moroccan doctors recommend to diversify the sources of acquisition of vaccines and to bypass the logic of “treating unilaterally” with a specific company. All this is part of the logic that the Kingdom can obtain collective immunity for Moroccans by next May.

The Moroccan authorities have had to face the facts and have confirmed that they have not yet received anything as of today and therefore have no other recourse than to rely on Chinese or even British calendars to start a vaccination campaign which we prided ourselves on being the first in the world to launch.

To this end, Azzedine Ibrahimi, professor and director of the biotechnology laboratory at the Faculty of Medicine and Pharmacy of Rabat and member of the scientific committee for the fight against the coronavirus, affirms that ” the vaccine approach remained the definitive and effective solution to disrupt the chain of propagation of the virus and prevent infection “, Noting that” Morocco has been and will remain faithful to these principles which determine the acquisition of the product and the vaccination of its citizens in a collective or massive way “.

The director of the biotechnology laboratory of the Faculty of Medicine of Mohammed V University in Rabat called for ” the need to activate communication about the vaccine delay, and adopt more transparency so as not to live in ambiguity and hatred, to question oneself and to live in fear of the unknown “. Professor Ibrahimi further underlined that “ all vaccines that Morocco may acquire in the future will meet the scientific, medical, pharmaceutical and legal standards and controls in force in the world, documented in the recommendations of the World Health Organization (WHO) “.

Before adding, ” the Directorate of Medicines and Pharmacy and the Advisory Committee for Emergency Licensing adhere to and will adhere to the sacred principles that frame the licensing process for medicines and vaccines in our country, which are based on safety, l efficiency, manufacturing quality and parallel pharmacovigilance “.

Ibrahimi felt that “ the issue is related to the health and safety of Moroccans “, And went on to explain:” With regard to Sinopharm, this company has submitted its license file and it is under discussion between the Directorate of Medicines and Pharmacy and the Advisory Committee on Licenses. I confirm here that this vaccine will only be approved if all the data from its clinical trials are attached to the dossier, while meeting all the above criteria. “.

Regarding Astra Zeneca / Oxford, Ibrahimi specifies ” For the first time in the history of Morocco, a vaccine is approved under the global emergency procedure “, Adding” After a complete study of the file presented by AstraZeneca / Oxford, and after reviewing the published research and vaccine license dossier in Britain and India, it was cleared by the line ministry “.

Regarding the delay, Ibrahimi said he was ” due to the growing demand for vaccines ”, stressing that “The committee had proposed several channels to purchase the Johnson & Johnson vaccine, which would end its clinical trials in February, especially since parallel logistical use is available, and a dose is sufficient, to develop the immunity “.

Back to top button